A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

Stopped Stopped before approval due to ineffective drug

Conditions

• Non-small Cell Lung Cancer
• Stage IV Disease
• EGFR Unknown or Wild-type

Interventions

• DRUG: Tivozanib
• DRUG: Erlotinib
• OTHER: Standard of Care treatment

Sponsor

University of Utah